Bristol-Myers Squibb Company (ETR:BRM)
39.91
-0.09 (-0.23%)
Jun 27, 2025, 5:35 PM CET
ETR:BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.20B USD in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
1.84
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
81.15B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Bristol-Myers Squibb Company News
- 1 day ago - U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels - Wallstreet:Online
- 1 day ago - U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels - Benzinga
- 1 day ago - This Once Dominant Dividend Stock May Be About to Come Back to Life in July - 24/7 Wall street
- 3 days ago - Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug - CNBC
- 3 days ago - Cigna files antitrust case against Bristol Myers over Pomalyst sales - Seeking Alpha
- 10 days ago - Bristol Myers Squibb Announces Dividend - Wallstreet:Online
- 11 days ago - Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) - Wallstreet:Online
- 15 days ago - Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader at EHA 2025 - Wallstreet:Online